Challenges for the new Cancer Drugs Fund

Weale, Albert; Kieslich, Katharina; Wilson, James; Rumbold, Benedict; Max, Catherine; Rid, Annette

doi:10.1016/s1470-2045(16)00100-5

Cited by 8 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However there are also examples of classical policy subsystems existing, e.g. the joint working between NICE and NHS England on the creation of the new Cancer Drugs Fund (Littlejohns et al , ). However as new goals for controlling NHS total cost (as opposed to assessing cost‐effectiveness) became important and the financial crisis deepened goal conflict emerged and NICE's position moved to state 3.…”

Section: Resultsmentioning

confidence: 99%

“…The study data collection finished in 2013 but it is still possible to track the institutions. The development of the cancer drugs fund represented a definite goal conflict between the DH and NICE (Littlejohns 2016). Furthermore the establishment of NHS England and Public Heath England represents the entry of new principles in the health landscape and examples of how this relationship is likely to develop can be demonstrated by a range of new decisions, e.g.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Setting standards and monitoring quality in the NHS 1999-2013: a classic case of goal conflict

Knight

Littlejohns

Poole

et al. 2016

Int J Health Plann Mgmt

Self Cite

View full text Add to dashboard Cite

Abstract2013 saw the National Health Service (NHS) in England severely criticized for providing poor quality despite successive governments in the previous 15 years, establishing a range of new institutions to improve NHS quality. This study seeks to understand the contributions of political and organizational influences in enabling the NHS to deliver high‐quality care through exploring the experiences of two of the major new organizations established to set standards and monitor NHS quality. We used a mixed method approach: first a cross‐sectional, in‐depth qualitative interview study and then the application of principal agent modeling (Waterman and Meier broader framework). Ten themes were identified as influencing the functioning of the NHS regulatory institutions: socio‐political environment; governance and accountability; external relationships; clarity of purpose; organizational reputation; leadership and management; organizational stability; resources; organizational methods; and organizational performance. The organizations could be easily mapped onto the framework, and their transience between the different states could be monitored. We concluded that differing policy objectives for NHS quality monitoring resulted in central involvement and organizational change. This had a disruptive effect on the ability of the NHS to monitor quality. Constant professional leadership, both clinical and managerial, and basing decisions on best evidence, both technical and organizational, helped one institution to deliver on its remit, even within a changing political/policy environment. Application of the Waterman–Meier framework enabled an understanding and description of the dynamic relationship between central government and organizations in the NHS and may predict when tensions will arise in the future. © 2016 The Authors. The International Journal of Health Planning and Management Published by John Wiley & Sons Ltd.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Setting standards and monitoring quality in the NHS 1999-2013: a classic case of goal conflict

Knight

Littlejohns

Poole

et al. 2016

Int J Health Plann Mgmt

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, the role of PCI in those patients has not been investigated sufficiently, due to the small number of patients involved 32 . The controversy has been lasted to very recently, favorers insisted that R0 resection can be considered as a special form of complete remission, and thus PCI is also suitable for those patients 33 , opponents argued that BM incidence was quite low in these early-stage patients, and neurological effects brought by PCI might outweigh its possible benefits 10 . The focus of the debate is the value of PCI in p-stage I patients.…”

Section: Discussionmentioning

confidence: 99%

Prophylactic cranial irradiation in resected small cell lung cancer: A systematic review with meta-analysis

Yang

Zhang²,

Xiao-fang³

et al. 2018

J. Cancer

View full text Add to dashboard Cite

Background: The use of PCI in early operable patients with small cell lung cancer (SCLC) is still controversial. Therefore, we conducted a systematic review with meta-analysis to investigate the effects of PCI in resected SCLC patients.Methods: Relevant studies were identified from PubMed and EMBASE databases, the pooled hazard risks were obtained by the random-effects model. We also analyzed the brain metastasis (BM) risk in p-stage I patients without PCI.Results: Five retrospective studies were identified and a total of 1691 patients were included in our analysis, 315 of them received PCI. For all the resected patients, PCI was associated with improved overall survival (HR: 0.52, 95% CI: 0.33-0.82), and reduced brain metastasis risk (RR: 0.50, 95%CI: 0.32-0.78). However, with regard to p-stage I patients, no survival benefit was brought by PCI (HR: 0.87, 95% CI: 0.34-2.24). Moreover, the pooled analysis of 7 studies found that the 5-year brain metastasis risk was relatively low (12%, 95% CI: 8%-17%) for p-stage I patients without PCI.Conclusions: PCI might be associated with a favorable survival advantage and reduced BM risk in complete resected SCLC patients, except for p-stage I patients.

show abstract

“…A fund for innovative medicines was seen as more acceptable than a disease-type fund such as the Cancer Drugs Fund [15], but it should be a 'transition' fund. They highlighted that the advantages of a specific fund for RM would be especially to provide flexibility.…”

Section: "For Things That Go To Nice Whatever They Are That Absolutmentioning

confidence: 99%

The Emerging Landscape of Reimbursement of Regenerative Medicine Products in the UK: Publications, Policies and Politics

Mahalatchimy

Faulkner

2017

Regen. Med.

View full text Add to dashboard Cite

Aim: This paper aims to map the trends and analyze key institutional dynamics that constitute the policies for reimbursement of regenerative medicine (RM), especially in the UK. Materials & methods: Two quantitative publications studies using Google Scholar and a qualitative study based on a larger study of 43 semi-structured interviews. Results: Reimbursement has been a growing topic of publications specific to RM and independent from orphan drugs. Risk-sharing schemes receive attention among others for dealing with RM reimbursement. Trade organizations have been especially involved on RM reimbursement issues and have proposed solutions. Conclusion: The policy and institutional landscape of reimbursement studies in RM is a highly variegated and conflictual one and in its infancy.

show abstract

Challenges for the new Cancer Drugs Fund

Cited by 8 publications

References 8 publications

Setting standards and monitoring quality in the NHS 1999-2013: a classic case of goal conflict

Setting standards and monitoring quality in the NHS 1999-2013: a classic case of goal conflict

Prophylactic cranial irradiation in resected small cell lung cancer: A systematic review with meta-analysis

The Emerging Landscape of Reimbursement of Regenerative Medicine Products in the UK: Publications, Policies and Politics

Contact Info

Product

Resources

About